Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD255 Purified Low Endotoxin

Anti-Hu CD255 Purified Low Endotoxin

Anti-Hu CD255 Purified Low Endotoxin
Regulatory status
RUO
Antigen
CD255
Clone
CARL-1
Format
Purified Low Endotoxin
Reactivity
Human
Application
IHC, FC (QC tested), FUNC
Variant
0.1 mg
12-756-C100
In stock
130.00 USD
Variant
0.1 mg
11-261-C100
In stock
130.00 USD
Contact distributor
Product details
References
Isotype
Mouse IgG3 kappa
Specificity
The mouse monoclonal antibody CARL-1 recognizes an extracellular epitope of CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to induce apoptosis weakly in many cell types.
Application
IHC, FC (QC tested), FUNC
Application details
Functional application: Neutralization.
Flow cytometry: Recommended dilution: 1-4 µg/ml
Reactivity
Human
Immunogen
human CD255-transfected 2PK-3 cells
Other names
TNFSF12, APO3L, DR3LG, TWEAK, TNLG4A
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Low endotoxin azide free phosphate buffered saline (PBS) solution, 0.2 μm filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Product specific references:

Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108
PubMed
Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8.
PubMed
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec;146(3):540-9.
PubMed
Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 2003 Sep 19;278(38):36005-12.
PubMed
Brown SA, Ghosh A, Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 2010 Jun 4;285(23):17432-41.
PubMed
Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80.
PubMed
Variant
0.1 mg
12-756-C100
In stock
130.00 USD
Variant
0.1 mg
11-261-C100
In stock
130.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product